Debiopharm and Oncodesign Services Launch Strategic Collaboration to Propel Radiopharmaceuticals in Preclinical Research
Debiopharm Research & Manufacturing S.A. (Debiopharm, www.debiopharm.com), a Swiss-based global biopharmaceutical company aiming to cure cancer and infectious diseases, and Oncodesign Services (www.oncodesign-services.com), a leading CRO specialized in drug discovery and preclinical services, announce the execution of a license agreement for the use of the AbYlink™ technology for preclinical services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424538240/en/
AbYlink™ is a regio-selective bioconjugation technology ideally suited for preparing conjugates for use in therapeutic and non-invasive diagnostic applications. Oncodesign Services will use this cutting-edge technology to prepare antibody chelator conjugates for use in preclinical studies to gain insights into the predictive effectiveness of novel treatment approaches in Molecular Radiotherapy, and particularly Radioimmunotherapy in the context of cancer. A joint poster will be presented at the AACR Annual Meeting 2025 to demonstrate the use of the non-invasive technology in Radioimmunotherapy, targeting animal models bearing HER2+ tumors.
“We have demonstrated the effectiveness of this powerful technology to rapidly and covalently conjugate any off-the-shelf antibody in a single step with an imaging agent. Our strategic collaboration with Oncodesign Services allows broader access to and usage of non-invasive imaging applications and provides an innovative solution to biotech and pharma partners to integrate imagery in the development of new antibody- and ADC-based therapeutics,” commented Frédéric Lévy, Chief Scientific Officer at Debiopharm.
Aidan Synnott, CEO of Oncodesign Services, said, “We are pleased to integrate this cutting-edge technology into our portfolio for our clients. The AbYlink™ technology gives the advantage of generating reproducible batches of bioconjugated antibodies and ADCs that secure specificity and efficacy of targeted radiotherapy.”
About AbYlink™
AbYlink™ is a versatile and rapid regio-selective chemical conjugation technology for use to prepare diagnostic or therapeutic conjugates. This one-step method results in stable conjugation at defined and invariable sites on the Fc domain of an antibody or the like, with no impact on antigen-binding regions. It enables a seamless and reproducible conjugation of payloads (e.g., a chelator for radiolabeling, a fluorescent dye or a drug) to antibodies or ADCs. The universal applicability of the technology has been demonstrated for various antibody isotypes and payloads.
About Debiopharm Research & Manufacturing
Debiopharm Research & Manufacturing manufactures treatments for prostate cancer, breast cancer and precocious puberty, namely at its Martigny facility, where it employs two hundred people. It is a subsidiary of the pharmaceutical company Debiopharm, headquartered in Lausanne, Switzerland. Debiopharm is an innovative company, devoting over 90% of its resources to innovation and the development of new drugs. Its mission is to develop innovative therapies that target high unmet medical needs in oncology and infectious diseases. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then select pharmaceutical commercialization partners to maximize patient access globally.
For more information, please visit: www.debiopharm.com
Follow us on LinkedIn https://www.linkedin.com/company/debiopharminternational/
About Oncodesign Services
Oncodesign Services is a contract research organization specializing in drug discovery and preclinical development. The company works with global biopharma partners to advance therapies in oncology, inflammation and infectious diseases through integrated services in protein sciences, structural biology, medicinal chemistry, pharmaco-imaging, DMPK and in vivo/in vitro pharmacology. Oncodesign Services has European facilities in France and the Netherlands.
More information on the website www.oncodesign-services.com
Follow us on LinkedIn https://www.linkedin.com/company/oncodesign/
View source version on businesswire.com: https://www.businesswire.com/news/home/20250424538240/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curiosity Cube 2025: Merck’s Mobile Science Labs Tour Globally to Bring STEM Education to Students24.4.2025 14:00:00 CEST | Press release
Curiosity Cube tours Europe, North America, and for the first time, Africa Mobile science lab aims to reach 60,000 students in 19 countries Interactive lessons on artificial intelligence designed to spark students’ curiosity in STEM Merck, a leading science and technology company, today launched its global 2025 Curiosity Cube tour in Darmstadt, Germany. The solar-powered mobile science labs will bring hands-on STEM (science, technology, engineering and mathematics) experiences to students across Europe, North America, and for the first time, Africa. In 2025, the tour aims to reach 60,000 students worldwide. The initiative underscores Merck's commitment to inspiring enthusiasm for science and technology. Merck today also opened its Curiosity Labs™ STEM Center in Darmstadt with 11 interactive science lessons to complement the Curiosity Cube experience for local students year-round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/
UPS to Acquire Andlauer Healthcare Group for $1.6 Billion, Strengthening its Global Offerings in Complex Healthcare Logistics24.4.2025 13:30:00 CEST | Press release
Acquisition will Enhance End-to-End Capabilities and Service to Healthcare Customers Needing Temperature-Controlled Logistics Solutions in North America UPS(NYSE: UPS) today announced that it has entered into a definitive agreement to acquire Andlauer Healthcare Group Inc. (TSX: AND) (“AHG”), a leading North American supply chain management company headquartered in Canada and offering customized third-party logistics and specialized cold chain transportation solutions for the healthcare sector. Under the terms of the agreement, AHG shareholders will receive CAD $55.00 per share in cash, representing a total purchase price of approximately CAD $2.2 billion (USD $1.6 billion). This transaction will extend the global portfolio of end-to-end cold chain capabilities available to UPS Healthcare customers, who increasingly seek temperature-controlled and precision logistics solutions. “Next-generation treatments are driving more complexity than ever, expanding the needs of healthcare customer
MSCI Expands Private Assets Toolkit With Launch of Indexes Tracking Venture-Backed Companies24.4.2025 13:00:00 CEST | Press release
MSCI All Country Venture-Backed Private Company Indexes are designed to help investors and wealth managers allocate, analyze and benchmark a fast-evolving asset class MSCI Inc. (NYSE: MSCI) has launched two MSCI All Country Venture-Backed Private Company Indexes, advancing the firm’s commitment to empowering investors with clear, transparent insights on the performance of private assets globally. With these indexes, MSCI is applying decades of index construction expertise to calculate the performance of venture-backed private company shares based on secondary market transaction data. Private companies that receive funding from venture capital investors often operate in high-growth, technology-driven industries that have garnered growing interest from investors and wealth managers in recent years. While such companies do not trade on centralized exchanges, over-the-counter secondary markets play a key role in providing liquidity and facilitating price discovery. Venture-backed companies
Aztec Group and Lantern Form a Strategic Alliance to Elevate Fund Data Access and Client Experience in Private Markets24.4.2025 11:16:00 CEST | Press release
Private markets are at a tipping point – the demand for streamlined, accessible fund data is growing rapidly, driven by General Partners (GPs) and investors who expect greater transparency, speed, and collaboration. In response, Aztec Group, a leading fund and corporate services provider, has partnered with Lantern, an innovative data intelligence platform, to enhance how clients can access high-quality, on-demand fund data and enable data-driven decision-making. Will Relf, Director of Data at Aztec commented: “As the industry continues to evolve, access to high-quality, timely data is no longer a luxury - it’s a necessity. At Aztec, we are committed to ensuring our clients can operate with confidence, backed by trusted data. Working with Lantern further enhances our ability to provide clients with innovative solutions for on-demand fund data, fully integrated with our accounting records and other key data sources.” By utilising Lantern as a component of its broader data offering, Azte
Aqualung Carbon Capture Successfully Closes Phase 1 2025 Financing Round24.4.2025 10:33:00 CEST | Press release
Aqualung Carbon Capture (“Aqualung”), a pioneering leader in membrane carbon dioxide (CO2) capture and separation technology, is excited to announce the successful first close of its funding round. This round is backed by Aqualung’s Joint Development Agreement (JDA) partner, one of the largest global membrane manufacturers, along with other strategic investors including Liquid Gas Equipment Ltd (LGE), wholly owned by Babcock International Group, Tupras Ventures, and Delek Innovation, the CVC of Delek (US) Holdings. This capital raise represents a significant milestone in Aqualung’s mission to establish itself as a leading carbon capture company. Over the past four years, Aqualung’s pilot units have successfully demonstrated its innovative non-pressurized facilitated transport membrane solution to be cost effective and applicable across various industries, including natural gas processing, lime kilns, and waste-to-energy applications. These units will continue to underpin the commercial
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom